

Antonella Sistigu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3606179/antonella-sistigu-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37
papers

5,481
citations

22
h-index

41
g-index

41
ext. papers

7,275
ext. citations

10
avg, IF

4.59
L-index

#	Paper	IF	Citations
37	The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition. <i>Cancers</i> , 2021 , 13,	6.6	4
36	Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. <i>Cell Death and Differentiation</i> , 2021 , 28, 2060-2082	12.7	10
35	The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure. <i>Cells</i> , 2021 , 10,	7.9	6
34	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death 2020 , 8,		233
33	Assessment of IFN- γ and granzyme-B production by in "sitro" technology. <i>Methods in Enzymology</i> , 2020 , 631, 391-414	1.7	2
32	Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies. <i>Methods in Enzymology</i> , 2020 , 632, 39-54	1.7	
31	Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening. <i>Frontiers in Immunology</i> , 2020 , 11, 2166	8.4	19
30	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. <i>Cells</i> , 2020 , 9,	7.9	4
29	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. <i>Trends in Cell Biology</i> , 2019 , 29, 396-416	18.3	37
28	Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. <i>Cancer Immunology Research</i> , 2018 , 6, 658-670	12.5	21
27	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018 , 25, 486-541	12.7	2160
26	CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. <i>Gut</i> , 2018 , 67, 903-917	19.2	45
25	Replication stress response in cancer stem cells as a target for chemotherapy. <i>Seminars in Cancer Biology</i> , 2018 , 53, 31-41	12.7	23
24	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. <i>Onc Immunology</i> , 2017 , 6, e1314424	7.2	69
23	IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. <i>Onc Immunology</i> , 2017 , 6, e1317420	7.2	84
22	The added value of type I interferons to cytotoxic treatments of cancer. <i>Cytokine and Growth Factor Reviews</i> , 2017 , 36, 89-97	17.9	13
21	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017 , 280, 165-174	11.3	52

20	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. <i>Emerging Topics in Life Sciences</i> , 2017 , 1, 471-486	3.5	3
19	Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. <i>Cytokine and Growth Factor Reviews</i> , 2017 , 36, 67-77	17.9	46
18	Trial watch - inhibiting PARP enzymes for anticancer therapy. <i>Molecular and Cellular Oncology</i> , 2016 , 3, e1053594	1.2	18
17	LTX-315, CAPtivating immunity with necrosis. <i>Cell Cycle</i> , 2016 , 15, 1176-7	4.7	3
16	Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition. <i>Oncotarget</i> , 2016 , 7, 885-901	3.1	23
15	Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. <i>Molecular and Cellular Oncology</i> , 2015 , 2, e1012976	1.2	95
14	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015 , 350, 972-83	3.3	267
13	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. <i>Oncolmmunology</i> , 2015 , 4, e988042	7.2	21
12	Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014 , 20, 1301-9	50.5	596
11	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014 , 3, e955691	7.2	524
10	A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. <i>Journal of Immunotoxicology</i> , 2014 , 11, 337-46	3.1	38
9	CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. <i>Cancer Research</i> , 2014 , 74, 436-45	10.1	90
8	IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. <i>Neoplasia</i> , 2012 , 14, 1223-35	6.4	41
7	An immunosurveillance mechanism controls cancer cell ploidy. <i>Science</i> , 2012 , 337, 1678-84	33.3	299
6	Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. <i>Cancer Research</i> , 2011 , 71, 768-78	10.1	240
5	Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2011 , 17, 351-8	2.2	66
4	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. <i>Seminars in Immunopathology</i> , 2011 , 33, 369-83	12	217
3	Type I IFNs control antigen retention and survival of CD8(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. <i>Journal of Immunology</i> , 2011 , 186, 5142-50	5.3	86

2	Human immunodeficiency virus type 1 (HIV-1) protease inhibitors block cell-to-cell HIV-1 endocytosis in dendritic cells. <i>Journal of General Virology</i> , 2009 , 90, 2777-2787	4.9	6
1	Macrophages transmit human immunodeficiency virus type 1 products to CD4-negative cells: involvement of matrix metalloproteinase 9. <i>Journal of Virology</i> , 2007 , 81, 9078-87	6.6	20